Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
insomnia
Biotech
Takeda narcolepsy blockbuster hopeful secures double ph. 3 wins
Takeda is on track to submit its narcolepsy drug to regulators this fiscal year after the OX2R-selective agonist scored a pair of phase 3 wins.
James Waldron
Jul 14, 2025 5:51am
J&J's oral add-on aces phase 3 in major depressive disorder
May 29, 2024 11:55am
FDA clears Neurovalens' neurostim headset for chronic insomnia
Nov 6, 2023 10:19am
Idorsia lays off 300 staff after previewing cost cuts in July
Oct 24, 2023 10:30am
ResMed continues German expansion with Mementor buy
Aug 2, 2022 1:00pm
Pear Therapeutics predicts ripening revenue after SPAC pact
Mar 29, 2022 12:31pm
